Neurological morbidity and mortality associated with the endovascular treatment of cerebral arteriovenous malformations before and during the Onyx era

Restricted access

OBJECT

The widespread implementation of the embolic agent Onyx has changed the endovascular management of cerebral arteriovenous malformations (AVMs). Recent data suggest that outcomes following embolization and resection may have worsened in the Onyx era. It has been hypothesized that there may be increased complications with Onyx embolization and increased surgical aggressiveness in patients treated with Onyx. In this study the authors analyzed their institutional experience with the endovascular treatment of cerebral AVMs prior to and after the introduction of Onyx to determine factors associated with periprocedural neurological morbidity and mortality.

METHODS

A retrospective review was performed of all patients with cerebral AVMs undergoing embolization at the Barrow Neurological Institute from 1995 to 2012.

RESULTS

Endovascular treatment of 342 cerebral AVMs was performed over 446 treatment sessions (mean age 37.8 years, range 1–83 years). Clinical presentation included hemorrhage in 47.6%, seizures in 21.9%, headaches in 11.1%, and no symptoms in 10% of cases. The endovascular pretreatment strategy was preoperative in 78.9%, preradiosurgery in 9.1%, palliative in 5.3%, targeted in 4.4%, and curative in 2.3%. The median Spetzler-Martin grade was III. The mean number of arteries embolized was 3.5 (range 0–13 arteries), and the mean number of treatment sessions was 1.3 (range 1–4 sessions). Onyx was used in 105 AVMs (30.7%), and N-butyl cyanoacrylate (NBCA) without Onyx was used in 229 AVMs (67%). AVMs treated with Onyx had a higher mean number of arterial pedicles embolized than did NBCA cases (4.3 ± 2.7 vs 3.2 ± 2.4, respectively; p < 0.001) and a greater number of sessions (1.5 ± 0.7 vs 1.2 ± 0.5, respectively; p < 0.05). Unexpected immediate postprocedural permanent neurological deficits were present in 9.6% of AVMs, while transient deficits were present in 1.8%. There was 1 death (0.3%). Spetzler-Martin grade was not associated with differences in outcome, as permanent neurological deficits were observed in 12%, 9%, 13%, 11%, and 13% of AVMs for Spetzler-Martin Grades I–V, respectively (p = 0.91). The use of Onyx compared with NBCA was not associated with differences in periprocedural morbidity (p = 0.23). This lack of a difference persisted even when controlling for number of arteries and sessions (p = 0.14). Sex was not associated with differences in outcome.

CONCLUSIONS

Permanent and transient postprocedural neurological deficits were noted in 9.6% and 1.8% of all cases, respectively. AVM grade was not associated with endovascular outcome. Despite the greater number of sessions required and arteries embolized for Onyx cases, there was no statistically significant difference in the risk of neurological deficits following cerebral AVM embolization with Onyx and NBCA.

ABBREVIATIONSAVM = arteriovenous malformation; mRS = modified Rankin Scale; NBCA = N-butyl cyanoacrylate.
Article Information

Contributor Notes

Correspondence Cameron G. McDougall, c/o Neuroscience Publications, Barrow Neurological Institute, 350 W. Thomas Rd., Phoenix, AZ 85013. email: neuropub@dignityhealth.org.ACCOMPANYING EDITORIAL DOI: 10.3171/2014.9.JNS141419.INCLUDE WHEN CITING Published online March 27, 2015; DOI: 10.3171/2015.2.JNS131368.DISCLOSURE Dr. Kim is an owner of, and patent holder for, SPI Surgical, Inc; has served as a consultant to Aesculap and Microvention; and has received clinical or research support for the study described from Volcano Inc. Dr. McDougall has served as a consultant to Covidien (eV3) and Terumo (Microvention).

© AANS, except where prohibited by US copyright law.

Headings
References
  • 1

    Hamilton MGSpetzler RF: The prospective application of a grading system for arteriovenous malformations. Neurosurgery 34:271994

  • 2

    Kim LJAlbuquerque FCSpetzler RFMcDougall CG: Postembolization neurological deficits in cerebral arteriovenous malformations: stratification by arteriovenous malformation grade. Neurosurgery 59:53592006

    • Search Google Scholar
    • Export Citation
  • 3

    Loh YDuckwiler GR: A prospective, multicenter, randomized trial of the Onyx liquid embolic system and N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations. Clinical article. J Neurosurg 113:7337412010

    • Search Google Scholar
    • Export Citation
  • 4

    Lv XWu ZLi YYang XJiang C: Hemorrhage risk after partial endovascular NBCA and ONYX embolization for brain arteriovenous malformation. Neurol Res 34:5525562012

    • Search Google Scholar
    • Export Citation
  • 5

    Morgan MK: The failure of preoperative ethylene-vinyl alcohol copolymer embolization to improve outcomes in AVM management: case series. The American Academy of Neurological Surgery 73rd Annual MeetingScottsdale, ArizonaOctober 19–22, 2011Park Ridge, ILAmerican Association of Neurological Surgeons2011

    • Search Google Scholar
    • Export Citation
  • 6

    Morgan MKDavidson ASKoustais SSimons MRitson EA: The failure of preoperative ethylene-vinyl alcohol copolymer embolization to improve outcomes in arteriovenous malformation management: case series. J Neurosurg 118:9699772013

    • Search Google Scholar
    • Export Citation
  • 7

    Saatci IGeyik SYavuz KCekirge HS: Endovascular treatment of brain arteriovenous malformations with prolonged intranidal Onyx injection technique: long-term results in 350 consecutive patients with completed endovascular treatment course. J Neurosurg 115:78882011

    • Search Google Scholar
    • Export Citation
  • 8

    Starke RMKomotar RJOtten MLHahn DKFischer LEHwang BY: Adjuvant embolization with N-butyl cyanoacrylate in the treatment of cerebral arteriovenous malformations: outcomes, complications, and predictors of neurologic deficits. Stroke 40:278327902009

    • Search Google Scholar
    • Export Citation
  • 9

    Taylor CLDutton KRappard GPride GLReplogle RPurdy PD: Complications of preoperative embolization of cerebral arteriovenous malformations. J Neurosurg 100:8108122004

    • Search Google Scholar
    • Export Citation
TrendMD
Cited By
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 201 201 88
Full Text Views 295 193 8
PDF Downloads 230 135 3
EPUB Downloads 0 0 0
PubMed
Google Scholar